Skip to main content

Testing version — LOERadar is in active testing. Features and data may change.

Hub News Changes Search

LOERadar

FDA drug patent and exclusivity intelligence, assembled from public records.

Sponsored by

About Terms of Service Privacy Policy Log in

Attorney Advertising

© 2026 LOERadar · An informational research tool drawn from public records; it is not a law firm, does not provide legal advice, and its use does not create an attorney-client relationship.

DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE (DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE) | LOERadar

Viewing data from:

DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE

ANDA

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE | A211537 | TORRENT PHARMACEUTICALS LTD

1 strength0 unique patents0 unique exclusivities

Products (1)

#001 — 10MG;EQ 5MG BASE

AB

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Apr 6, 2026

No patent or exclusivity listings for this strength.